<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103374</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN10-PD/Nebuadom</org_study_id>
    <secondary_id>2010-023743-14</secondary_id>
    <secondary_id>2010-R38</secondary_id>
    <secondary_id>A101466-30</secondary_id>
    <nct_id>NCT02103374</nct_id>
  </id_info>
  <brief_title>Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State</brief_title>
  <acronym>Nebuadom</acronym>
  <official_title>Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Design studies of nebulization in COPD does not respond adequately to the clinically relevant
      question: the intervention of administering nebulized bronchodilators at home it is likely to
      make a profit, compared to the standard optimized treatment as defined by the recommendations
      of the SPLF, patients with severe COPD (stage III, FEV between 30% and 50% of the theoretical
      value) and very severe (stage IV, less than 30% of the theoretical value FEV)? The concept of
      profit in this context is based on criteria of dyspnea, quality of life, use of health system
      (exacerbations, hospitalizations, prescription of antibiotics and steroids ...).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score for quality of life, assessed by the questionnaire St Georges</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score for quality of life, assessed by the questionnaire VQ11</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score according Medical Research Council</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic Score Mortality assessed by the score BODE</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospitalizations</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Severe Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Atrovent + Bricanyl or Atrovent + Ventolin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule per day lactose (in addition to the standard optimized treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrovent + Bricanyl or Atrovent + Ventoline</intervention_name>
    <description>3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks</description>
    <arm_group_label>Atrovent + Bricanyl or Atrovent + Ventolin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule lactose during 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult

          -  COPD Patients stage 3 et 4

          -  Has not submitted an exacerbation in the 3 months preceding the pre-inclusion visit

          -  Weaned from tobacco for at least 6 months

          -  vaccinated against pneumococcal

          -  Have not been included in a pulmonary rehabilitation program during the 6 months
             preceding the screening visit inclusion

          -  Patient pre-included not showing exacerbation since the pre-inclusion visit

        Exclusion Criteria:

          -  Patient under nebulizer or has been treated with nebulized bronchodilators at home
             over the last 6 months

          -  Patient with an indication of oxygen is expected in the coming year

          -  Progressive malignant disease known

          -  Patient under non-invasive ventilation (NIV) for less than 6 months or NIV provided in
             the following year

          -  Patient known to be colonized by Pseudomonas aeruginosa, A. xylosoxidans, Burkholderia
             cepacia or Stenotrophomonas maltophilia

          -  Patients with severe cardiovascular disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice DIOT, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Orl√©ans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>weaned tobacco</keyword>
  <keyword>Has not submitted an exacerbation in the past 3 months</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

